MEDICAL ONCOLOGY

CLOSED TO RECRUITMENT — SINGAPORE

Abbrev. Title

CA209-74W Checkmate74W

Protocol Title

A Randomized, Multi-Center, Double-Blinded, Placebo-Controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination with Trans-Arterial Chemoembolization (TACE) in Patients with Intermediate-Stage Hepatocellular Carcinoma (HCC)

CLEE011A3201C RIGHT Choice

A Phase II Randomized Study of the Combination of Ribociclib plus Goserelin Acetate with Hormonal Therapy versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients with Hormone Receptor-Positive/ HER2-Negative Inoperable Locally Advanced or Metastatic Breast Cancer

D3614C00001 CAPItello-290

A Phase III Double-Blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclitaxel Vs Placebo+Paclitaxel as First-Line Treatment for Patients with Locally Advanced (Inoperable) or Metastatic TNBC

D9673R00005 HER2Real

A Multicountry, Multicentre, Non-interventional Retrospective Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients with HER2-positive Unresectable or Metastatic Breast Cancer

IMMU-132-13 Tropics-04

A Randomized Open-Label Phase III Study of Sacituzumab Govitecan versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer

MS200095-0031

INSIGHT-2

A Phase II, Two Arm Study to Investigate Tepotinib Combined with Osimertinib in MET Amplified, Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy

PXL 252853 LIQUIK-01 Liquid Biopsy for Detection of Actionable Genomic Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

SKYSCRAPER-08 YO42138

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab plus Tiragolumab in Combination with Paclitaxel and Cisplatin compared with Paclitaxel and Cisplatin as First-Line Treatment in Patients with Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Y-mAbs 202

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients with High-Risk Neuroblastoma in First Remission. An International, Open-Label, Uncontrolled, Single-Arm, Multicenter, Phase 2 Trial CLINICAL TRIALS